Merck & Co., Inc. (NYSE:MRK) gained FDA approval for KEYTRUDA QLEX™ injection. In Q2 2025, the company reported an Adjusted EPS of $2.13, surpassing expectations. Worldwide sales of $15.8 billion slightly missed, declining 2%, attributed to a drop in Gardasil sales in China. KEYTRUDA sales surged by 9% to $8.0 billion.

On September 19, 2025, Merck received FDA approval for KEYTRUDA QLEX™ injection for subcutaneous administration in adults. Dr. J. Thaddeus Beck praised the approval, noting its significance for patients and healthcare providers. With new approvals, Merck attracts investors with a 4% dividend yield.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company founded in 1891. Known for research-driven approaches to tackle diseases, it develops prescription medicines, vaccines, and animal health products. Operating from New Jersey, Merck offers a dividend yield of 4% that appeals to investors.

Read more at Yahoo Finance: Merck Gains FDA Approval for KEYTRUDA QLEX and Supports Dividend Appeal